S. Ramirez

Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study

N. Michael, R. Canter, N. Rouphael, 2021, medRxiv.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

M. Andrasik, J. Kublin, M. McElrath, 2021, The New England journal of medicine.

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

N. Michael, N. Rouphael, C. Diazgranados, 2022, The Lancet Infectious Diseases.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Holly Janes, David C Montefiori, Peter B Gilbert, 2013, The New England journal of medicine.

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

Kwaku Poku Asante, D. Follmann, M. Robb, 2023, eClinicalMedicine.

Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline

Z. Moodie, K. Otwombe, M. Malahleha, 2023, BMC Medical Research Methodology.